Antibody-based cancer therapy.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are crucial in cancer therapy, primarily by disrupting tumor cell signaling pathways to halt cell cycle progression and inhibit tumor growth.
• mAbs also leverage innate immune system effector functions to facilitate the destruction of malignant cells, contributing to their clinical efficacy.

Purpose of the Study:

• To explore the potential of combining monoclonal antibody (mAb) treatment with other cancer immunotherapy modalities to induce tumor-specific immunity.
• To address the need for strategies that enhance adaptive antitumor immunity through combination immunotherapies.

Main Methods:

• Enhancing active antitumor immune responses through mAb treatment by potentiating co-stimulation and blocking co-inhibition.
• Increasing tumor immunogenicity via elevated tumor peptide expression as a strategy within mAb-based therapies.

Main Results:

• Preclinical and clinical studies indicate that monoclonal antibodies (mAbs) possess the capability to promote tumor-specific active immunity.
• The review summarizes the functional characteristics, mechanisms of action, and clinical applications of mAbs in cancer treatment.

Conclusions:

• Combination immunotherapies utilizing mAbs show significant potential for augmenting adaptive antitumor immunity.
• Monoclonal antibodies can be instrumental in not only direct tumor cell targeting but also in fostering a robust, tumor-specific immune response.